MENOPAUSE THERAPEUTICS QUESTIONS &
ELABORATED CORRECT ANSWERS
1. perimenopausal onset of menstrual irregularity
2. perimenopausal FSH •FSH >10-12 IU/L on first 2-3 days of menstrual
cycle
3. menopause •12 consecutive months of amenorrhea
4. menopause FSH •FSH >40 IU/L; ovaries have ceased function
5. do females who had a • Females who have had a hysterectomy (removal
hys-terectomy have of uterus) may or may not have symptoms of
symptoms of menopause
menopause?
6. vasomotor symptoms •Hot flashes, night sweats, sleep disturbances, mood
changes
7. Vulvovaginal Atrophy • Vulvovaginal dryness, irritation or itching,
(VVA)/Gen-itourinary vaginal dis-charge
Symptoms of Menopause • Dyspareunia: diflcult or painful intercourse
(GSM) • Urinary symptoms of urgency, dysuria or
recurrent UTIs
8. goals of therapy •Decrease symptoms or severity of symptoms
• Improve quality of life
• Address modifiable risk factors
9. decrease symptoms or • Continue treatment for at least one month to
severity of symptoms assess treat-ment ettect
• Side ettects leading to discontinuation?
premenstrual like symptoms; vaginal bleeding
1/
17
,MENOPAUSE THERAPEUTICS QUESTIONS &
ELABORATED CORRECT ANSWERS
10. address modifiable risk factorssmoking, BMI, alcohol use, diet
11. MHT, HT, HRT •MHT = Menopausal hormone therapy
- Preferred broad term used to describe estrogen
therapy or estrogen + progestin therapy
2/
17
, MENOPAUSE THERAPEUTICS QUESTIONS &
ELABORATED CORRECT ANSWERS
• HT = Hormone therapy
• HRT = Hormone replacement therapy
12. According to the North American •Hormone Therapy remains the most ettective
treatment
Menopause Society (NAMS) Po- for VMS/GSM and is shown to prevent bone loss and
sition Statement, what frac-ture. Individualized treatment approach that
remains the most effective considers risk to benefit
treatment for VMS/GSM and
is shown to pre-vent bone
loss and fracture?
13. what does ACOG recommend for •Lowest dose of HRT
HRT? • Shortest duration possible
• Decrease possible risks of ADEs
14. MRT absolute contraindications •Undiagnosed abnormal genital bleeding
• History of breast cancer
• Estrogen or progesterone-dependent
neoplasia
• History or active VTE/DVT
• Active/recent thromboembolic diagnosis:
MI/Stroke
• Liver disease
15. MRT relative contraindications •Uncontrolled HTN
• Hypertriglyceridemia
• Impaired liver function
• Fluid retention
• Severe hypocalcemia
• Ovarian cancer
• Exacerbations of endometriosis
3/
17
ELABORATED CORRECT ANSWERS
1. perimenopausal onset of menstrual irregularity
2. perimenopausal FSH •FSH >10-12 IU/L on first 2-3 days of menstrual
cycle
3. menopause •12 consecutive months of amenorrhea
4. menopause FSH •FSH >40 IU/L; ovaries have ceased function
5. do females who had a • Females who have had a hysterectomy (removal
hys-terectomy have of uterus) may or may not have symptoms of
symptoms of menopause
menopause?
6. vasomotor symptoms •Hot flashes, night sweats, sleep disturbances, mood
changes
7. Vulvovaginal Atrophy • Vulvovaginal dryness, irritation or itching,
(VVA)/Gen-itourinary vaginal dis-charge
Symptoms of Menopause • Dyspareunia: diflcult or painful intercourse
(GSM) • Urinary symptoms of urgency, dysuria or
recurrent UTIs
8. goals of therapy •Decrease symptoms or severity of symptoms
• Improve quality of life
• Address modifiable risk factors
9. decrease symptoms or • Continue treatment for at least one month to
severity of symptoms assess treat-ment ettect
• Side ettects leading to discontinuation?
premenstrual like symptoms; vaginal bleeding
1/
17
,MENOPAUSE THERAPEUTICS QUESTIONS &
ELABORATED CORRECT ANSWERS
10. address modifiable risk factorssmoking, BMI, alcohol use, diet
11. MHT, HT, HRT •MHT = Menopausal hormone therapy
- Preferred broad term used to describe estrogen
therapy or estrogen + progestin therapy
2/
17
, MENOPAUSE THERAPEUTICS QUESTIONS &
ELABORATED CORRECT ANSWERS
• HT = Hormone therapy
• HRT = Hormone replacement therapy
12. According to the North American •Hormone Therapy remains the most ettective
treatment
Menopause Society (NAMS) Po- for VMS/GSM and is shown to prevent bone loss and
sition Statement, what frac-ture. Individualized treatment approach that
remains the most effective considers risk to benefit
treatment for VMS/GSM and
is shown to pre-vent bone
loss and fracture?
13. what does ACOG recommend for •Lowest dose of HRT
HRT? • Shortest duration possible
• Decrease possible risks of ADEs
14. MRT absolute contraindications •Undiagnosed abnormal genital bleeding
• History of breast cancer
• Estrogen or progesterone-dependent
neoplasia
• History or active VTE/DVT
• Active/recent thromboembolic diagnosis:
MI/Stroke
• Liver disease
15. MRT relative contraindications •Uncontrolled HTN
• Hypertriglyceridemia
• Impaired liver function
• Fluid retention
• Severe hypocalcemia
• Ovarian cancer
• Exacerbations of endometriosis
3/
17
